Vaccination against HPV in Brazil: What is New in the Year 2017?
Vacinação contra o Papilomavírus Humano no Brasil: o que há de novo em 2017?
DOI:
https://doi.org/10.15446/revfacmed.v65n3.63104Descargas
letter to the editor
DOI: https://doi.org/10.15446/revfacmed.v65n3.63104
Vaccination against HPV in Brazil: What is New in the Year 2017?
Vacinação contra o Papilomavírus Humano no Brasil: o que há de novo em 2017?
Received: 05/03/2017. Accepted: 22/03/2017.
Marcos Roberto Tovani-Palone1 • Taís Tovani-Sanches2
1 University of São Paulo - Faculty of Medicine of Ribeirão Preto - Ribeirão Preto - São Paulo - Brazil.
2 Cesumar University Center - Course of Medicine of the Cesumar University Center - Maringá - Paraná - Brazil.
Corresponding author: Taís Tovani-Sanches. Cesumar University Center. Av. Guedner, 1610, Zona 8, CEP 87050-900. Phone number: +55 44 30276360. Maringá. Brazil. Email: tais.sanches1@gmail.com.
Tovani-Palone MR, Tovani-Sanches T. Vaccination against HPV in Brazil: What is New in the Year 2017? Rev. Fac. Med. 2017;65(3):539. English. doi: https://doi.org/10.15446/revfacmed.v65n3.63104.
Tovani-Palone MR, Tovani-Sanches T. [Vacinação contra o Papilomavírus Humano no Brasil: o que há de novo em 2017?]. Rev. Fac. Med. 2017;65(3):539. English. doi: https://doi.org/10.15446/revfacmed.v65n3.63104.
Dear editor,
We would like to discuss briefly new information regarding the article “Evolução do sistema público de saúde no Brasil frente ao estágio atual da prevenção do câncer de colo uterino em mulheres jovens e adolescentes” (1).
In 2017, the Ministry of Health of Brazil started to implement the quadrivalent vaccination against human papillomavirus (HPV) for boys aged 12 to 13 years, thus making Brazil the first South American country that offers this vaccine for boys in the National Immunization Calendar through mass vaccination (2,3). In addition, the age group for vaccination of children and adolescent girls against HPV was extended from 9 to 14 years (2).
It is worth mentioning that in 2020, the vaccination of boys will be done beginning at age 9 (2,3). Today, vaccination against HPV is still provided to girls aged 9 to 26 years infected with human immunodeficiency virus (HIV), and vaccination to boys with the same condition was initiated in 2017 (2).
All these changes intend to decrease the number of HPV infection cases, as well as related deaths (3). However, according to Sanches et al. (2017), several barriers have been found that hinder the effective implementation of the vaccination against HPV in children and adolescents (1).
In consequence, we believe that improvements are necessary, especially regarding health education in schools and specific professional training to attend to the needs of this age group. Only when these requirements are met, it can be possible to provide adequate assistance to these individuals, with a significant increase in vaccination rates.
Conflicts of interest
None declared by the authors.
Funding
None declared by the authors.
Acknowledgements
None declared by the authors.
References
1.Sanches TT, Siqueira-Oliveira T, Papp-Moretti C, Tovani-Palone MR, Hishinuma G. Evolução do sistema público de saúde no Brasil frente ao estágio atual da prevenção do câncer de colo uterino em mulheres jovens e adolescentes. Rev. Fac. Med. 2017;65(1):115-20. http://doi.org/cd86.
2.Brasil. Ministério da Saúde. Nota Informativa No. 311, de 2016/CGPNI/DEVIT/SVS/MS. Mudanças no Calendário Nacional de Vacinação para o ano de 2017. Brasília: Secretaria de Vigilância em Saúde; 2016 [cited 2017 Mar 04]. Available from: https://goo.gl/mEHNyv.
3.Portal Brasil. Tire dúvidas sobre a vacinação contra o HPV para meninos. Governo do Brasil; 2017 [cited 2017 Mar 04]. Available from: https://goo.gl/WbRnWg.
![](https://revistas.unal.edu.co/index.php/revfacmed/article/download/63104/version/49868/64746/371507/014.jpg)
Iván “Ivanquio” Benavides
“El niño vacío” – 014
Técnica: tinta, color digital
Recibido: 5 de marzo de 2017; Aceptado: 22 de marzo de 2017
Dear editor,
We would like to discuss briefly new information regarding the article "Evolução do sistema público de saúde no Brasil frente ao estágio atual da prevenção do câncer de colo uterino em mulheres jovens e adolescentes" 1.
In 2017, the Ministry of Health of Brazil started to implement the quadrivalent vaccination against human papillomavirus (HPV) for boys aged 12 to 13 years, thus making Brazil the first South American country that offers this vaccine for boys in the National Immunization Calendar through mass vaccination 2,3. In addition, the age group for vaccination of children and adolescent girls against HPV was extended from 9 to 14 years 2.
It is worth mentioning that in 2020, the vaccination of boys will be done beginning at age 9 2,3. Today, vaccination against HPV is still provided to girls aged 9 to 26 years infected with human immunodeficiency virus (HIV), and vaccination to boys with the same condition was initiated in 2017 2.
All these changes intend to decrease the number of HPV infection cases, as well as related deaths 3. However, according to Sanches et al. (2017), several barriers have been found that hinder the effective implementation of the vaccination against HPV in children and adolescents 1.
In consequence, we believe that improvements are necessary, especially regarding health education in schools and specific professional training to attend to the needs of this age group. Only when these requirements are met, it can be possible to provide adequate assistance to these individuals, with a significant increase in vaccination rates.
Acknowledgements
None declared by the authors.
References
Referencias
Sanches TT, Siqueira-Oliveira T, Papp-Moretti C, Tovani-Palone MR, Hishinuma G. Evolução do sistema público de saúde no Brasil frente ao estágio atual da prevenção do câncer de colo uterino em mulheres jovens e adolescentes. Rev. Fac. Med. 2017;65(1):115-20. http://doi.org/cd86.
Brasil. Ministério da Saúde. Nota Informativa No. 311, de 2016/CGPNI/DEVIT/SVS/MS. Mudanças no Calendário Nacional de Vacinação para o ano de 2017. Brasília: Secretaria de Vigilância em Saúde; 2016 [cited 2017 Mar 04]. Available from: https://goo.gl/mEHNyv.
Portal Brasil. Tire dúvidas sobre a vacinação contra o HPV para meninos. Governo do Brasil; 2017 [cited 2017 Mar 04]. Available from: https://goo.gl/WbRnWg.
Cómo citar
APA
ACM
ACS
ABNT
Chicago
Harvard
IEEE
MLA
Turabian
Vancouver
Descargar cita
CrossRef Cited-by
1. Marcos Roberto Tovani-Palone. (2017). Human papillomavirus vaccination for boys in Brazil. Medwave, 17(08), p.e7079. https://doi.org/10.5867/medwave.2017.08.7079.
Dimensions
PlumX
Visitas a la página del resumen del artículo
Descargas
Licencia
Derechos de autor 2017 Revista de la Facultad de Medicina
![Creative Commons License](http://i.creativecommons.org/l/by/3.0/88x31.png)
Esta obra está bajo una licencia Creative Commons Reconocimiento 3.0 Unported.
Derechos de autor
Los autores deben aceptar transferir a la Revista de la Facultad de Medicina los derechos de autor de los artículos publicados. La editorial tiene el derecho del uso, reproducción, transmisión, distribución y publicación en cualquier forma o medio. Los autores no podrán permitir o autorizar el uso de la contribución sin el consentimiento escrito de la revista. Estos archivos están disponibles en https://goo.gl/EfWPdX y https://goo.gl/6zztk4 y deben cargarse en el paso 4 del envío OJS (archivos complementarios).
La carta de cesión de derechos de autor y la de responsabilidad de autoría deben ser entregadas junto con el original.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).